Vincent A. Vultaggio
SVP of Finance & Principal Accounting OfficerMr. Vincent A. Vultaggio is Interim Principal Accounting Officer of Zentalis Pharmaceuticals, Inc. from April 5, 2024 and serves as its Senior Vice President, Finance. He has served as the Vice President of Finance of Zentalis Pharmaceuticals, Inc. since February 2023 and has public accounting and corporate finance experience. He joined Zentalis as Controller/Senior Director, Finance in January 2019 and was subsequently promoted to Executive Director, Finance and Controller in January 2021. Mr. Vultaggio was the Director of Accounting for Halozyme Therapeutics (“Halozyme”) from November 2015 to January 2019. Mr. Vultaggio held financial positions of varying levels of responsibility at life sciences and technology companies. Mr. Vultaggio began his career as an auditor at Ernst & Young LLP from September 2004 through April 2011, where he last served as a Manager, Assurance Services. Mr. Vultaggio received a B.A. in Accountancy and an M.A. in Accountancy and Financial Management from the University of San Diego in 2004.
Positions
- Company NameZentalis Pharmaceuticals, Inc.Stock CodeZNTLPositionSVP of Finance & Principal Accounting OfficerColleagues
- JMJulie M. EastlandCEO, President & Director
- SDScott D. MyersIndependent Chairman of the Board
- JBJames B. BucherChief Legal Officer & Corporate Secretary
- IBIngmar BrunsChief Medical Officer
- RJRobert J. DiVastoChief Technical Officer
- DMDavid Michael JohnsonIndependent Director
- EKEnoch K. KariukiIndependent Director
- JSJan SkvarkaIndependent Director
